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GLYCEMIC VARIABILITY AND COMPLICATIONS IN PATIENTS 
WITH DIABETES MELLITUS: EVIDENCE FROM A SYSTEMATIC
REVIEW OF THE LITERATURE
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OBJECTIVES: Large prospective clinical studies in both type 1 Diabetes Mellitus 
(T1DM) and type-2 diabetes mellitus (T2DM) have shown that high HbA1c levels is 
a strong predictor of diabetic complications. New data suggest that variability in 
glucose values, speciﬁ cally excursions in postprandial hyperglycemia, may also play a 
signiﬁ cant role in the risk of microvascular and macrovascular complications. The aim 
of this review was to assess the published evidence for an association between glycemic 
variability and diabetic complications in patients with DM. METHODS: A systematic
review of studies published in English between 1990-November 2008 was undertaken.
Studies in patients with T1DM or T2DM reporting a) measures of glycemic variability; 
and b) its impact on the development or progression of diabetic complications were
assessed. RESULTS: Eighteen studies were identiﬁ ed. Seven and 11 studies focused on
T1DM and T2DM patients, respectively. Studies in patients with T1DM revealed that
glucose variability has little impact on the development of diabetic complications. 
Only in two T1DM studies did glucose variability have a signiﬁ cant association with
prevalent peripheral neuropathy and presence of nephropathy, but not with other
complications. Among T2DM studies, a signiﬁ cant positive association between
glucose variability and the development or progression of diabetic complications 
was reported in 10 of 11 studies. The risk of progression to diabetic retinopathy 
was signiﬁ cantly increased among patients in higher quartiles of glycemic variability 
(CV-FPG): 2nd quartile OR  3.47 (95%CI:1.06–11.5); 3rd quartile OR  3.66
(95%CI:1.12–12); and 4th quartile OR  6.95 ((95%CI:2.1–22.4). Similarly, the risk 
of all cause and cardiovascular mortality was signiﬁ cantly higher among patients in 
the 2nd and 3rd tertiles of CV-FPG. CONCLUSIONS: This overview of the available 
evidence suggests that glucose variability may be an independent predictor of compli-
cations regardless of HbA1c levels in patients with T2DM. Better control of blood 
glucose excursions may reduce the risk of these complications.
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OBJECTIVES: To evaluate the ﬁ nancial impact on the INHS following the introduc-
tion of cinacalcet for patients with intractable PHPT or in those whom parathyroid-
ectomy (PTX) is contraindicated. METHODS: The number of patients eligible for 
cinacalcet was estimated by literature and local demographic information. The BIM
simulates the impact of PHPT management in patients with or without cinacalcet. 
Resources to manage patients not receiving cinacalcet included drugs for treatment of 
secondary osteoporosis, visits and diagnostics and a second PTX for patients refrac-
tory to their ﬁ rst PTX. Resources to manage patients receiving cinacalcet included 
60 mg/day cinacalcet and all of the above except the re-surgery. The total cost was
calculated by applying the resources used, the INHS tariffs for visits, diagnostics and 
surgery and the reimbursed price for drugs. RESULTS: It was estimated that in the 
ﬁ rst three years following market introduction, just 113, 320 and 490 out of 1400 
eligible patients with PHPT would be placed on cinacalcet therapy respectively. The
baseline cost of PHPT management resulted in €794 per patient, per year (€256 for 
drugs, €314 for re-surgery, €224 for diagnostics). The introduction of cinacalcet 
resulted in a cost of €3698 per patient per year with cinacalcet costing €4380, partially
offset by savings due to less other drugs ( €256), avoiding PTX ( €314) and less 
diagnostics (€112). The total incremental annual budget increase due to addition of 
cinacalcet was €417,864, €1,183,332 and €1,811,978 in the ﬁ rst three years, respec-
tively CONCLUSIONS: Because of the low prevalence of intractable PHPT, the 
incremental ﬁ nancial BI on the INHS following the introduction of cinacalcet would 
be very small and partially offset by savings from less health care resource use. Based
on these calculations, the INHS granted reimbursement for cinacalcet in this new
indication in 2008.
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ECONOMIC EVALUATION OF LONG TERM SOMATOSTATIN
ANALOGS IN THE TREATMENT OF ACROMEGALY IN MEXICO: 
MONOTHERAPY VS SEQUENTIAL THERAPY
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OBJECTIVES: To compare cost and effectiveness between monotherapy with octreo-
tide LAR vs sequential therapy with lanreotide Autogel and octreotide LAR (long 
term somatostatin analogs) in the treatment of patients with acromegaly, from an 
institutional perspective, in the Mexican setting. METHODS: Cost-effectiveness 
analysis using a decision tree model that simulates the cost and efﬁ cacy of the treat-
ment of acromegaly with long term somatostatin analogs: monotherapy with octreo-
tide LAR vs. sequential therapy with lanreotide Autogel and octreotide LAR or 
vice versa, for a temporary horizon of 18 months. The effectiveness measure was the
percentage of patients achieving a reduction in IGF-1 and growth hormone levels, 
obtained from clinical trials published in international literature. Only direct medical 
costs were considered in the analysis. Costs were estimated using prices of 2008 and 
are expressed in US dollars (exchange rate of 11.14 pesos/ 1 US dollar). RESULTS:
Octreotide LAR monotherapy lead to 30% of patients achieving a reduction of 
IGF-1 and growth hormone to safe levels, whereas sequential therapy achieved 37.8% 
patients with hormone reduction to safe levels. The treatment with lanreotide 
Autogel/octreotide LAR showed the best average cost $24,792.3, per acromegalic 
patient treated, followed by the treatment with octreotide LAR/ lanreotide Autogel
with a cost of $28,925.8 and ﬁ nally octreotide LAR monotherapy with a cost of 
$29,514.0. According to incremental analysis, the treatment with lanreotide Autogel/
octreotide LAR is the dominant alternative. Univariate sensitivity and probability
analyses results show the same trend as the basic scenario. CONCLUSIONS: Lanreo-
tide Autogel/octreotide LAR is the best cost-effective acromegaly treatment, from
the institutional perspective in the Mexican context.
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OBJECTIVES: The aim of this health economic analysis was to assess the cost-
effectiveness of insulin detemir (IDet)  oral antidiabetics (OAD) versus OAD alone
or neutral protamine Hagedorn (NPH)  OAD in patients with type 2 diabetes, based 
on the Czech sub-cohort type 2 patients of the large observational study PREDIC-
TIVE. METHODS: A published and validated computer CORE Diabetes Model was
used to project long-term economic and clinical outcomes in a cohort of type 2 dia-
betes patients treated with either IDet  OAD versus OAD alone or neutral NPH 
OAD, in the Czech setting. Probabilities of complications, management costs adjust-
ments (including complications and treatment costs) were derived from the Czech
surveys from 2007. Future costs and clinical beneﬁ ts were discounted at 3,5% per 
annum. RESULTS: IDet  OAD treatment was projected to improve life expectancy 
by approximately 0.53 versus OAD /0,26 years versus NPH  OAD (9,33/9,27 versus 
8,80/9,01 years) and quality-adjusted life expectancy by 0.29/0,68 quality-adjusted 
life years (5,75/6,02 versus 5,46/5,34 QALYs). Treatment and complication costs 
associated with IDet treatment were higher over patient lifetimes than with OAD with 
difference 76 862 CZK (260 628 CZK/QALY) and lower than with NPH  OAD with 
difference 151 409 CZK (CZK/QALY dominant). CONCLUSIONS: CORE diabetes 
T2 patients sub-cohort simulation in 35 years perspective from PREDICTIVE study 
has demonstrated acceptable cost-effectiveness for patients with type 2 diabetes treated 
IDetOAD. IDet  OAD treatment was projected to be associated with improvements
in life expectancy, QALYs and acceptable or cost saving compared to OAD/ NPH
OAD. Sensitivity analyses show cost-effectiveness result to be robust.
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OBJECTIVES: To estimate the cost-effectiveness of rapid-acting insulin analogues
(RAIA) compared to regular human insulin (HI), for the treatment of diabetes mellitus 
(DM). This information may assist policy makers in making informed decisions on
reimbursement of RAIAs. METHODS: An economic evaluation, from the perspective
of a third-party provincial payer, was conducted using the Center for Outcomes 
Research (CORE) Diabetes Model (CDM). Clinical outcomes (e.g., A1c and hypogly-
caemia) were derived from recent meta-analyses. Costs and utilities, both discounted
at 5%, were obtained from published sources. Sensitivity analyses were performed to
test the robustness of results. RESULTS: Type 1 DM (T1DM) – insulin aspart was 
more effective (0.055 quality-adjusted life years (QALYs)) and less costly ($620) than 
regular HI. The incremental cost-utility ratio (ICUR) for insulin lispro relative to
regular HI was $28,996 per QALY gained (difference ($) in cost, $182; $ QALYs, 
0.006). Type 2 DM (T2DM) – the ICUR for insulin aspart compared to regular HI, 
was $22,488 per QALY gained ($ cost, $333; $ QALYs, 0.015). The ICUR for insulin 
lispro, relative to regular HI, was $130,865 per QALY gained ($ cost, $784; $QALYs, 
0.006). Results were sensitive to variations of parameters in sensitivity analyses. 
CONCLUSIONS: Compared with regular HI, the use of RAIAs for the treatment of 
DM was associated with relatively low ICURs, with the exception of insulin lispro in 
patients with Type 2 DM, which was associated with a relatively high ICUR.
